Cardiff Oncology, Inc.
NASDAQCRDF short interest utilization hits 92.56%, near its 52-week peak of 100%, signaling extremely tight share availability for borrowing despite flat cost-to-borrow at 11.17%.
Snapshot as of 29 Jun 2026
No long-form analysis yet for CRDF. Pulse alerts and the live data picture are available on ORTEX.
Open CRDF on ORTEX →Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CRDF — free to start on ORTEX.
Sign up for free →Open CRDF on ORTEX